| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 09/06/2001 | US20010020042 Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 09/06/2001 | US20010020013 Polymerase inhibitors |
| 09/06/2001 | US20010020006 Dipeptidyl peptidase; antidiabetic agents |
| 09/06/2001 | DE10006887A1 Modulators of regulatory protein RS1, useful for treating diabetes or tumors and for increasing drug transport, control concentration of transport proteins in plasma membranes |
| 09/05/2001 | EP1130103A2 Nucleic acid from Tetrahymena coding for a trieterpenoid-cyclase, its production and use |
| 09/05/2001 | EP1130098A2 Mammalian osteoregulins |
| 09/05/2001 | EP1130087A2 A method to identify compounds that alter the apoptotic process |
| 09/05/2001 | EP1130027A1 Memno peptides, process for preparation and use thereof |
| 09/05/2001 | EP1130017A2 Azole derivatives and their use as superoxide radical inhibitors |
| 09/05/2001 | EP1129715A1 Use of magnesium, calcium and silicon for the healing of different diseases and to the general well-being |
| 09/05/2001 | EP1129711A2 Pinolenic acid against diabetes |
| 09/05/2001 | EP1129706A2 Use of cGMP PDE5 inhibitors for the treatment of neuropathy |
| 09/05/2001 | EP1129351A2 COMPOSITIONS AND METHODS RELATING TO THE PEROXISOMAL PROLIFERATOR ACTIVATED RECEPTOR-$g(a) MEDIATED PATHWAY |
| 09/05/2001 | EP1129350A1 Methods for identifying modulators of bs69 activity |
| 09/05/2001 | EP1129217A2 Compositions and methods of disease diagnosis and therapy |
| 09/05/2001 | EP1129189A2 Human cell surface receptor proteins |
| 09/05/2001 | EP1129181A2 Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity |
| 09/05/2001 | EP1129112A2 Peptides containing a cholesterol recognition sequence and their uses |
| 09/05/2001 | EP1129110A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 09/05/2001 | EP1129096A2 Crf receptor antagonists and methods relating thereto |
| 09/05/2001 | EP1129089A1 Spiro-indolines as y5 receptor antagonists |
| 09/05/2001 | EP1129084A2 Ppar gamma ligands |
| 09/05/2001 | EP1129078A2 Indazole derivatives with 5-ht2 receptor activity |
| 09/05/2001 | EP1129077A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 09/05/2001 | EP1129074A2 Antrhranilic acid amides and the use thereof as medicaments |
| 09/05/2001 | EP1128845A1 Combinations comprising a beta-agonist and a further antdiabetic agent |
| 09/05/2001 | EP1128840A1 Prevention of muscle mass loss with leptin receptor ligands |
| 09/05/2001 | EP1128834A1 Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide |
| 09/05/2001 | EP1128827A1 Pharmaceutical composition for modified release insulin sensitiser |
| 09/05/2001 | EP1128813A1 An inhalation system |
| 09/05/2001 | EP0832061B1 Benzamide derivatives and their use as vasopressin antagonists |
| 09/05/2001 | EP0793646B1 Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus |
| 09/05/2001 | EP0760677B1 A pharmaceutical preparation comprising glucagon |
| 09/05/2001 | CN1311775A Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 09/05/2001 | CN1311773A Neuropeptide Y5 receptor antagonists |
| 09/05/2001 | CN1311772A New 3-aryl-2-hydoxy-propionic acid derivative I |
| 09/05/2001 | CN1311769A New 3-aryl-2-hydroxypropionic acid derivative III |
| 09/05/2001 | CN1311767A Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders |
| 09/05/2001 | CN1311688A Synthetic somatostatin immunogen for growth promotion in farm animals |
| 09/05/2001 | CN1311687A Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance |
| 09/05/2001 | CN1311686A Pulmonary delivery of active agents |
| 09/05/2001 | CN1311682A Pharmaceutical compositions and uses for androst-5-ene-3beta, 17 beta-diol |
| 09/05/2001 | CN1311676A Compound that inhibit the binding of integrins to their receptors |
| 09/05/2001 | CN1311032A Tea for reducing weight and lowering fat and its preparing method |
| 09/05/2001 | CN1311023A Medicine for anti-thrombus and cleaning blood and preparing method |
| 09/05/2001 | CN1311017A Medicine for curing diabetes |
| 09/05/2001 | CN1310997A Composite coenzyme Q 10 health nutriment |
| 09/05/2001 | CN1070487C Hexahydronaphthalene ester derivatives, their prepn. and their therapeutic uses |
| 09/05/2001 | CN1070484C Hypolipidemic 1,4-benzothiazepine-1,1-dioxides |
| 09/05/2001 | CN1070371C Medicine for treating HIV-seropositive individuals medicine |
| 09/04/2001 | US6285537 Stress-follower circuit configuration |
| 09/04/2001 | US6284903 Treating hyperlipidemia, obesity and impaired glucose tolerance/noninsulin dependent diabetes mellitus without adversely affecting energy metabolism |
| 09/04/2001 | US6284787 Use of R-(+)-α-lipoic acid, R-(−)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae |
| 09/04/2001 | US6284785 1-arenesulfonyl-2-aryl-pyrrolidine and pyridine derivatives |
| 09/04/2001 | US6284768 Src family SH2 domain inhibitors |
| 09/04/2001 | US6284766 9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands |
| 09/04/2001 | US6284748 Antidiabetic agent |
| 09/04/2001 | US6284730 Administering parathyroid hormone |
| 09/04/2001 | US6284538 Oligonucleotide used for diabetes and cancer treatment |
| 09/04/2001 | US6284268 Cyclosporin, synergistic |
| 08/30/2001 | WO2001062954A2 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| 08/30/2001 | WO2001062932A1 Antagonistic selective binding agents of osteoprotegerin binding protein |
| 08/30/2001 | WO2001062923A2 Transporters and ion channels |
| 08/30/2001 | WO2001062905A2 Integrin antagonists |
| 08/30/2001 | WO2001062775A2 Novel antiarrhythmic peptides |
| 08/30/2001 | WO2001062765A2 Small molecule modulators of g protein-coupled receptor six |
| 08/30/2001 | WO2001062757A1 Novel compounds |
| 08/30/2001 | WO2001062756A1 Pyridinylimidazoles |
| 08/30/2001 | WO2001062750A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 08/30/2001 | WO2001062747A1 8,8a-dihydro-indeno[1,2-d]thiazole derivatives with a sulphonamido or sulphono substituent in the 2 position, a method for production thereof and use thereof as a medicament |
| 08/30/2001 | WO2001062746A1 8,8a-dihydro-indeno[1,2-d]thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g. anorectic agents |
| 08/30/2001 | WO2001062745A1 Substituted 8, 8a-dihydro-3ah-indeno[1,2-d]thiazoles, a method for their production and their use as medicaments |
| 08/30/2001 | WO2001062742A1 Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
| 08/30/2001 | WO2001062737A2 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 08/30/2001 | WO2001062736A1 Aryl fused azapolycyclic compounds |
| 08/30/2001 | WO2001062733A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 08/30/2001 | WO2001062729A1 Novel compounds |
| 08/30/2001 | WO2001062728A1 Novel compounds |
| 08/30/2001 | WO2001062723A1 VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2α-POSITION |
| 08/30/2001 | WO2001062721A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | WO2001062712A1 (2s)-aminoindan derivatives, a process for their preparation and their use as selective dopamine d3 ligands |
| 08/30/2001 | WO2001062705A2 Aminoalcohol derivatives |
| 08/30/2001 | WO2001062341A2 Combination product for the treatment of obesity |
| 08/30/2001 | WO2001062312A1 Foam-forming wound dressing |
| 08/30/2001 | WO2001062297A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | WO2001062295A1 Drugs containing combined active ingredients |
| 08/30/2001 | WO2001062266A2 Use of dpp-iv inhibitors for the treatment of diabetes |
| 08/30/2001 | WO2001062252A1 Tyrosine kinase inhibitors |
| 08/30/2001 | WO2001062250A1 Thiazolium compounds and treatments of disorders associated with protein aging |
| 08/30/2001 | WO2001062244A1 Agents ameliorating sickness behaviors |
| 08/30/2001 | WO2001062236A2 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| 08/30/2001 | WO2001062213A1 Squalane containing ultra fine particles of burning residue of carbon and method for producing the same |
| 08/30/2001 | WO2001062108A1 Water containing soluble fiber |
| 08/30/2001 | WO2001062086A1 Nutritional intervention composition for enhancing and extending satiety |
| 08/30/2001 | WO2001012806A3 Odorant-binding human proteins fixing hydrophobic ligands: polypeptides and polynucleotides coding for said polypeptides and uses thereof |
| 08/30/2001 | WO2001012606A3 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 08/30/2001 | WO2001012195A3 Use of morphine derivatives as medicaments for the treatment of neuropathic problems |
| 08/30/2001 | WO2001012127A3 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 08/30/2001 | WO2000040733A9 Human cyclic nucleotide pdes |
| 08/30/2001 | WO2000040614A9 Characterization of the soc/crac calcium channel protein family |